CompletedNot Applicable

Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers

United States20 participantsStarted 2023-01-15

Plain-language summary

Ultraviolet light A (UVA) causes oxidization of guanine to mutagenic 8-Oxoguanine (8-OxoG) and the most frequent and best characterized mutation in mitochondrial DNA (mtDNA), a deletion of 4,977 base pairs, called the "common deletion", a marker of photoaging.

Who can participate

Age range22 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Population: Inclusion criteria: * Healthy subjects * 22-65 years of age * Fitzpatrick skin types II and III Exclusion criteria: * Pregnancy * Personal history of skin cancer * History of abnormal photosensitivity * Tobacco smoker * History or being exposed to other forms of radiation (other than sunlight) * Using any drug/medication that might alter the response of skin to UVA irradiation * Unable to undergo skin biopsies * History of abnormal scarring * History of exposure to the treated areas with external beam X-ray or non-solar UV light irradiation

What they're measuring

Title: Double-Blind Study to measure and compare the Mean Percent Reduction UVA induced premutagenic and photoaging markers 8-oxo-dG and the common deletion in 20 subjects treated with CANNAXR and Vehicle and exposed to 3X their individual MED-UVA

Timeframe: 2 weeks

Trial details

NCT IDNCT05279495

SponsorMINO Labs, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-04-01

View on ClinicalTrials.gov More Photoaging trials